SMIadviser.org will not be accessible after 11:59pm ET on July 8, 2024. Thank you for your support over the past six years!
An APA and SAMHSA Initiative American Psychiatric Association logo Substance Abuse and Mental Health Services Administration (SAMHSA) logo
  • Clinicians
    • Clinicians Home
    • Consult Request
    • Knowledge Base
    • Education Catalog
    • Centers Of Excellence
  • Individuals & Families
    • Guidance
    • Knowledge Base
    • Person-First Language
  • Our Tools
    • SMI Adviser App
    • My Mental Health Crisis Plan
    • Clozapine Dose Planner
    • LAI Conversion Tool
    • LAI Explorer
  • About Us
  • Calendar
  • Contact

Clozapine Dose Planner

This tool has been developed to assist you in thinking about the pharmacokinetics of clozapine. The information here is synthesized from clinical research studies and may not be representative of an individual patient response.

This tool is not intended to influence prescribing practices but should be used to provide an estimate of what plasma level might be obtained, given the parameters of age, gender, weight, and smoking status.

Clinical decisions should be based upon your knowledge of the patient’s situation and history and the plasma level itself, not an estimate. Clozapine levels should be drawn in the morning 12 hours after the last dose. If there is a morning clozapine dose, it should be held until the level can be drawn.
Which of the following scenarios would you like to explore?(Required)
Smoker
Sex
Please note, this tool was not developed to be used for transgender individuals.
Clozapine dose predictions may not be accurate for individuals with very low or very high body weight.
Clozapine dose predictions may not be accurate for individuals with very low or very high body weight.
This tool is not meant to serve as a guideline for individual patient management. It should not be considered as statement of the standard of care or inclusive of all considerations relevant to care. Any action suggested by this tool should not be used by a clinician without evaluation of each individual patient’s specific conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Effort has been made in preparing this tool to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of release. Nevertheless, APA provide the tool on an “as is” basis and makes no warranties, expressed or implied, regarding the tool, including that the information contained herein is free from error. APA assumes no responsibility and disclaims all liability for any injury or damage to persons or property arising out of or related to any use of this tool or for any errors or omissions.
Administered by American Psychiatric Association logo
Funded by Substance Abuse and Mental Health Services Administration (SAMHSA) logo
About SMI Adviser
  • Mission Statement
    Our mission is to advance the use of a person-centered approach to care that ensures people who have SMI find the treatment and support they need. For clinicians, we offer access to education, data, and consultations so you can make evidence-based treatment decisions. For patients, families, friends, people who have questions, or people who care for someone with SMI, we offer access to resources and answers from a national network of experts.
  • Grant Statement
    Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
  • Terms & Privacy
  • Copyright
Sitemap
  • Clinicians
  • About Us
  • Contact

SMI Adviser is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of the website's resources, please call us at 202-559-3900 for assistance.

Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
© 2025 American Psychiatric Association. All rights reserved.
(Esc)

Go to top of page